IL2 and inflammatory bowel disease: Clinical studies have demonstrated that low doses of IL-2 can mediate immunomodulation and specifically expand and activate the Treg cell population, thus serving as a potential treatment strategy for patients with IBD (Klatzmann and Abbas, 2015).